Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth
© Telang et al.; licensee BioMed Central Ltd. 2012
Received: 25 May 2012
Accepted: 17 August 2012
Published: 23 August 2012
Constitutive activation of Ras in immortalized bronchial epithelial cells increases electron transport chain activity, oxygen consumption and tricarboxylic acid cycling through unknown mechanisms. We hypothesized that members of the Ras family may stimulate respiration by enhancing the expression of the Vb regulatory subunit of cytochrome c oxidase (COX).
We found that the introduction of activated H-RasV12 into immortalized human bronchial epithelial cells increased eIF4E-dependent COX Vb protein expression simultaneously with an increase in COX activity and oxygen consumption. In support of the regulation of COX Vb expression by the Ras family, we also found that selective siRNA-mediated inhibition of K-Ras expression in A549 lung adenocarcinoma cells reduced COX Vb protein expression, COX activity, oxygen consumption and the steady-state concentration of ATP. We postulated that COX Vb-mediated activation of COX activity may be required for the anchorage-independent growth of A549 cells as soft agar colonies or as lung xenografts. We transfected the A549 cells with COX Vb small interfering or shRNA and observed a significant reduction of their COX activity, oxygen consumption, ATP and ability to grow in soft agar and as poorly differentiated tumors in athymic mice.
Taken together, our findings indicate that the activation of Ras increases COX activity and mitochondrial respiration in part via up-regulation of COX Vb and that this regulatory subunit of COX may have utility as a Ras effector target for the development of anti-neoplastic agents.
KeywordsMitochondria Glycolysis Tricarboxylic acid cycle Electron transport chain Oncogene
Activating mutations of the Ras guanosine nucleotide-binding proteins cause insensitivity to GTPase-activating proteins (GAP) and are common genetic alterations of human cancers. Activated GTP-bound Ras family members promote survival and proliferation in part by increasing glucose uptake and flux into the synthesis of ribose-5-phosphate and lactate[2–4]. Recently, constitutive activation of Ras also has been found to increase mitochondrial tricarboxylic acid (TCA) cycle activity and oxygen consumption and to sensitize cells to the ATP-depleting and cytotoxic effects of electron transport perturbation using the complex I inhibitor rotenone. These data suggested that activation of the Ras signalling pathway in immortalized cells might increase reliance on mitochondrial metabolism for energy and anabolism. In support of this conclusion, disruption of mitochondrial function caused by loss of the mitochondrial transcription factor A (TFAM) gene reduced tumorigenesis in an oncogenic K-Ras-driven mouse model of lung cancer. Additionally, elevated glycolytic flux into multiple mitochondrial TCA cycle products has been observed in human lung tumors in vivo and these tumors commonly express mutated Ras. Last, several agents that selectively disrupt mitochondrial function (termed mitocans) have been found to interfere with the bioenergetic functions of cancer cells and suppress tumor growth[10, 11]. Understanding the precise mechanisms whereby Ras family members regulate mitochondrial metabolism and the functional importance of this metabolic effect for the tumor-forming potential of Ras-transformed cells may yield new molecular targets for the development of anti-cancer agents.
The mitochondrial electron transport chain consists of four respiratory enzyme complexes that serve to create a proton gradient. Cytochrome c oxidase (COX), or complex IV, is the terminal enzyme in the electron transport chain which pumps protons from the matrix into the intermembrane space forming an electrochemical gradient across the inner mitochondrial membrane to generate ATP. COX functions to catalyze electron transfer from cytochrome c to molecular oxygen via four redox centers. Although COX only has ~20% total control over ATP synthesis, studies in vivo have indicated that COX represents the rate-limiting step of the electron transport chain. COX is composed of thirteen different subunits[16, 17] - subunits I-III are encoded by the mitochondrial genome whereas the other ten subunits are encoded by nuclear genes. The nuclear subunits are synthesized as precursor proteins and imported into the mitochondria where the complex is assembled. Within the thirteen subunit complex, the nuclear-encoded subunit Vb serves a unique role in the regulation of COX activity as this particular subunit faces the matrix side and is sufficient to increase both COX activity and oxygen consumption in HeLa cervical adenocarcinoma cells. Interestingly, the expression of subunit Vb has been found to be increased in neoplastic cells and to positively correlate with the progression of cells from normal epithelia to invasive carcinoma. These observations suggest that COX Vb not only may serve as an essential regulatory subunit of COX but also may be mediating the increase in mitochondrial metabolism caused by activation of Ras.
In the current study, we demonstrate that introduction of the activated H-RasV12 GTPase into immortalized bronchial epithelial cells increases COX Vb protein expression, COX activity and oxygen consumption and that COX Vb protein expression is required to maintain the high oxygen consumption and ATP concentration of A549 lung adenocarcinoma cells that express oncogenic K-Ras. We also find that selective COX Vb inhibition markedly inhibits soft agar colony formation and poorly differentiated A549 xenograft growth in mice without affecting proliferation in vitro. Taken together, these observations suggest that COX may be an appropriate molecular target for the development of anti-neoplastic agents.
H-RasV12 increases COX Vb protein expression and activity
COX Vb protein expression is dependent on eukaryotic translation initiation factor 4E (eIF4E) expression
Selective inhibition of K-Ras suppresses COX Vb activity, oxygen consumption and intracellular ATP in A549 cells
Selective K-Ras inhibition also reduced COX activity, oxygen consumption and the steady-state concentration of ATP in the A549 cells (Figure3D-F). These data coupled to the observations that ectopic expression of H-RasV12 increases COX Vb expression and COX activity further support the conclusion that COX Vb expression is regulated by Ras signalling.
Suppression of COX Vb expression decreases anchorage-independent growth as soft agar colonies
Suppression of COX Vb expression decreases anchorage-independent growth as tumors in athymic mice
In this study, we found that introduction of oncogenic H-RasV12 into immortalized human bronchial epithelial cells enhanced eIF4E-dependent COX Vb protein expression, COX activity and oxygen consumption. Conversely, selective siRNA silencing of K-Ras expression in A549 cells was observed to selectively suppress COX Vb protein expression, COX activity and oxygen consumption. Transfection of the A549 cells with two independent siRNA molecules specific for COX Vb caused a marked decrease in COX activity, oxygen consumption, ATP, anchorage-independent soft agar colony growth and xenograft growth in athymic mice. Taken together, these data suggest that a metabolic regulatory pathway thus exists whereby Ras signalling activates eIF4E activity which, in turn, leads to increased COX Vb protein expression, COX activity and oxygen consumption. The reduction in xenograft growth that was caused by COX Vb inhibition was associated with reduced histological markers of high-grade poorly differentiated cells which may indicate that COX activity is required for the aggressiveness of certain lung adenocarcinomas. These observations support an examination of potential correlations between COX Vb protein expression by human lung adenocarcinomas and clinical outcomes including growth rates, response to therapy and overall survival. Additionally, these results indicate that COX may have utility as a target for the development of anti-cancer therapeutics, especially against tumors in which the Ras signalling pathway is activated.
Ras proto-oncogenes encode membrane-bound 21 kDa guanosine nucleotide-binding proteins that transduce mitogenic signals from tyrosine-kinase receptors. Whereas Ras mutations occur in ~30 percent of human cancers, activation of Ras signalling pathways (e.g. via epidermal growth factor receptor [EGFR] amplifications) is a nearly ubiquitous characteristic of human cancers. K-RasG12D transgenic mice develop tumors which express COX Vb, and activation of the Ras/cAMP/protein kinase A pathway in Saccharomyces cerevisiae increases COX activity and oxygen consumption. Additionally, the ratio of COX Vb to COX I or COX II expression markedly increases during the progression from normal human prostate epithelium to invasive prostate carcinoma, a transformation that is dependent on the downstream Ras signalling pathways MAPK and PI3K/AKT. The current study adds to this body of literature, demonstrating that the discrete introduction of the human oncogene H-RasV12 into immortalized human bronchial epithelial cells not only increases protein expression of the regulatory Vb subunit but also oxygen consumption and COX activity. Perhaps more importantly, the current study demonstrates for the first time that COX Vb expression by Ras-transformed lung adenocarcinoma cells is required for their ability to grow as a high-grade, poorly differentiated tumor in athymic mice.
We previously reported that introduction of activated Ras into immortalized cells simultaneously increased glycolytic flux to lactate, TCA cycle activity and oxygen consumption. Ras oncoproteins also directly increase the expression of uncoupling protein (UCP)-1, and UCP-2 expression has been found to be increased in most human colon adenocarcinomas in which up to 60% contain K-Ras mutations[28, 29]. The mitochondrial TCA cycle and cytoplasmic GADPH reactions require oxidized NAD+ which is produced by LDH in the cytosol or by electron transport chain activity in the mitochondria. We postulate that Ras activation may cause simultaneous stimulation of COX activity and uncoupling of ATP synthase from the proton gradient in order to facilitate the continued oxidation of NADH to NAD+ necessary for glycolytic flux and TCA cycling.
Expression of oncogenic H-RasV12 sensitizes immortalized cells to electron transport chain disruption with rotenone suggesting that activation of Ras signalling also may confer greater reliance on the electron transport chain for energy requirements. Given that we have found that introduction of H-RasV12 increases COX Vb protein expression and COX activity relative to immortalized cells, we speculate that the COX Vb subunit and the entire COX complex serve as essential metabolic downstream effectors of Ras. Dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase (PDH) kinase and thus a stimulator of PDH and flux into the TCA cycle, has been observed to increase oxygen consumption but to reduce tumor growth. In contrast, we have found that selective inhibition of COX Vb reduced both oxygen consumption and tumor growth. Although the precise mechanism and rationale for these differences are not well understood, we postulate that the disruption of NADH oxidation caused by either the diversion of pyruvate away from LDH or by the inhibition of electron transport chain activity (Figure4F) may yield a similarly deleterious effect on anabolic pathways such as the TCA cycle that are required for tumor growth.
In conclusion, we find that activation of the Ras signalling pathway increases COX activity in part via eIF4E-dependent enhancement of COX Vb protein expression and that COX is required for tumorigenic growth. The continued characterization of the regulatory mechanisms and rationale for increased COX activity in transformed cells should allow us to tailor rational anti-metabolic approaches for the treatment of cancer.
Cell lines and culture
A549 human lung adenocarcinoma cells (American Type Culture Collection, Manassas, VA) were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, Grand Island, NY) supplemented with 10% FCS and gentamicin sulfate (HyClone, Logan, UT). Normal human bronchial epithelial cells expressing telomerase and SV40 large T antigen (hT/LT) and activated Ras (H-RasV12) were gifts from Dr. B. J. Rollins, Dana Farber Cancer Institute. hT/LT and H-RasV12 cells were grown in BEGM medium formulated with SingleQuots (bovine pituitary extract, recombinant human epidermal growth factor, hydrocortisone, insulin, epinephrine, tri-iodothyronine, transferrin, gentamicin, amphotericin B and retinoic acid) (Lonza, Walkersville, MD). Media contained physiologic glucose (5.5 mM) and glutamine (1 mM), and cells were cultured under 21% O2 (normoxia) with 5% CO2 at 37°C (Heraeus).
Cells were plated at 8 x 104 cells/well in 6 well tissue culture plates and incubated at 5% CO2 and 37°C in DMEM as described above for 24 hours. Cells were then transfected with siRNA using RNAiMax (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. For inhibition of COX Vb in A549 cells, two siRNA constructs were designed, one specific for the open reading frame region of COX Vb (COX Vb- ORF) and a second specific for the 3’ untranslated region (COX Vb- 3’UTR), termed COX Vb1 and COX Vb2 respectively. The target sequences (sense strands) were as follows: Vb1 = AGUAGGCUGCAUCUGUGAA and Vb2 = CAGUAAAGACUAGCCAUUG. siRNAs against lamin A/C and RNAiMax alone were included as controls. COX Vb siRNA duplexes were synthesized by Dharmacon (Lafayette, CO). For the inhibition of eIF4E, hT/LT, H-RasV12 or A549 cells were transfected with pre-synthesized eIF4E siRNA (Ambion, Austin, TX). For the inhibition of K-Ras, A549 cells were transfected with pooled K-Ras siRNA (Santa Cruz Biotechnology, Santa Cruz, CA).
Western blot analysis
Western blot analysis was carried out on protein lysates from A549, hT/LT, and H-RasV12 cells transfected with siRNA as described above. Briefly, equal amounts of total protein (30 μg) from each sample were run on a 4-20% gradient SDS-PAGE gel under reducing conditions and proteins were transferred to PVDF membranes (BioRad, Hercules, CA). Membranes were probed with a 1:500 dilution of anti-COX Vb polyclonal mouse antibody (Invitrogen), a 1:1000 dilution of anti-H-Ras antibody or a 1:100 dilution of anti-K-Ras antibody (both from Santa Cruz). Immunoreactive proteins were visualized by incubating membranes with horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG antibody (1:10000) followed by reaction with ECL Plus (Amersham, St. Louis MO). Membranes were subsequently probed with a mouse monoclonal β-actin antibody (Sigma, St. Louis MO) as an internal protein loading control. Experiments were repeated four times. All data are expressed as the mean ± SD of three experiments. Statistical significance was assessed by the unpaired two-tail T-test.
COX activity assay
COX activity was measured as described in Campian et al.. Briefly, lysates of cells (at a concentration of 2 × 106 cells/ml) were prepared in 0.25 M sucrose, 40 mM potassium chloride, 2 mM EGTA, 1 mg/ml bovine serum albumin, and 20 mM Tris–HCl (pH 7.2) and disrupted by 3 1 second bursts using a microtip Fisher model 100 sonic dismembrator at scale 3 (on a scale of 0–10 of the 100-watt maximum power output) (Fisher Scientific, Pittsburgh, PA). The lysate was centrifuged at 4000 × g for 10 min, the pellet discarded and the supernatant was used for COX assays. Assays contained 30 μg of protein and were performed at 37°C in 200 μl reaction volumes. The assay involved the addition of 40 μM ferrocytochrome c in an isosmotic medium (10 mM KH2PO4 (pH 6.5), 1 mg/ml bovine serum albumin, 0.3 M sucrose) containing 2.5 mM n-dodecyl maltoside to permeabilize mitochondrial membranes. The activity was calculated from the rate of decrease in absorbance of ferrocytochrome c at 550 nm (ε = 19.1 mM–1 cm–1). All data are expressed as the mean ± SD of three experiments. Statistical significance was assessed by the unpaired two-tail T-test.
Cells were detached with trypsin-EDTA and centrifuged at 1000 rpm for 5 minutes in complete culture medium. Oxygen consumption was measured using a Strathkelvin 782 Oxygen Meter (Strathkelvin Instruments, Glasgow, Scotland, UK). Respiration rates were measured using 1 × 106 cells suspended in a total volume of 525 μL DMEM containing 10% FBS at 37°C for 10 minutes. A starting O2 concentration of 240 μM was assumed based on O2 solubility at conditions in this laboratory (1 atm/37°C). Experiments were repeated four times. The data shown are mean ± SD of three experiments. Statistical significance was assessed by the unpaired two-tail T- test.
Cells were washed (while still adherent) with cold PBS x1, lysed with passive lysis buffer (1X, Molecular Probes, Invitrogen) added directly to the plates and immediately harvested by scraping. The lysates were flash frozen (to −80°C) and thawed (to 37°C) once to accomplish complete lysis and then centrifuged (at 4°C) for 30 seconds to clear the lysates. Intracellular ATP levels were determined using a bioluminescence assay (Molecular Probes) utilizing recombinant firefly luciferase and its substrate, D-luciferin. The luminescence was read in a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA) at 560 nm. The ATP values were calculated using an ATP standard curve. The protein concentrations of the lysates were estimated using the bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL) and ATP was expressed as nmol per mg protein. Experiments were repeated five times. All data are expressed as the mean ± s.d. of three experiments. Statistical significance was assessed by the unpaired two-tail T- test.
NAD+/NADH ratio assay
A549 cells treated with siRNA species for 48 hours were lifted using trypsin - EDTA, washed twice with cold PBS and 105 cells were pelleted by centrifugation. NAD+ and NADH concentrations were measured using an enzyme-based assay (E2ND-100, Bioassay Systems, Hayward, CA). Briefly, the cell pellets were homogenized in either NAD+ extraction buffer (containing 0.40% HCl) or NADH extraction buffer (containing 0.40% NaOH), extracts heated to 60°C and then assay buffer (containing Tris(hydroxymethyl)aminomethane 3.0%, and BSA 0.10%) and extraction buffer (to neutralize the extracts) were added. Following centrifugation, supernatants were mixed with working reagent containing assay buffer, lactate dehydrogenase, diaphorase, lactate and tetrazolium dye (MTT) and optical density at 565 nm was recorded at time zero and at 15 minutes using a 96 well plate reader spectrophotometer. The difference in absorbance was compared with standard solutions and used to calculate NADH and NAD+ concentrations. All data are expressed as the mean ± s.d. of three experiments. Statistical significance was assessed by the unpaired two-tail T-test.
For measurements of contact-dependent growth, cells were grown in appropriate media as described above. Following siRNA transfections, cells were grown for 48 h. Proliferation was determined using trypan blue exclusion. Cells were incubated in 20% trypan blue (Sigma) for 5 minutes. Cells excluding trypan blue were counted using a standard hemocytometer (Hausser Scientific) to determine the total number of viable cells. All data are expressed as the mean ± SD of five experiments. Statistical significance was assessed by the unpaired two-tail T-test.
Soft agar colony formation assay
A549 cells with or without Vb siRNA transfection for 48 hours were plated at a density of 1 × 104 cells/60-mm plate sandwiched by 3 ml bottom agar (0.6 %) and 3 ml top agar (0.3%). Cells were fed every three days by adding a new layer of top agar. After 21 days, colonies were counted in random 1 cm2 sections of each plate. All data are expressed as the mean ± SD of three experiments. Statistical significance was assessed by the unpaired two-tail T-test.
A549 lung adenocarcinoma cells stably transfected with either COX Vb or a control shRNA were collected from exponential growth phase culture in DMEM supplemented with 10% FCS. Cells were washed twice and re-suspended in PBS (5 × 107 cells/ml). Groups of CD1 female athymic mice (20 gm) were injected s.c. with 0.1 ml of the cell suspension (5 × 106 cells). The tumors were followed from the time of appearance until 21 days. Tumor masses were determined in a blinded fashion with Vernier calipers according to the following formula: mass(mg) = (width, mm)2 × (length, mm)/2. All data are expressed as the mean ± SD of two experiments (n = 8 per group). Statistical significance was assessed by the unpaired two tail T-test. At the end of the experiment, mice were euthanized and the tumors were excised, fixed in formalin, embedded in paraffin and stained with Hematoxylin and Eosin or with anti-CA IX (Abcam, Cambridge, MA).
This work was supported by the Kentucky Lung Cancer Research Program (JC), the James Graham Brown Cancer Center (JC), the National Cancer Institute (1 R01 CA116428-01; JC, 1 R01 CA140991-01; ST) and the American Cancer Society (RSG-10-021-01-CNE; ST). We gratefully acknowledge helpful discussions with Otto Grubraw.
- Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007, 26: 3291-3310. 10.1038/sj.onc.1210422View ArticlePubMedGoogle Scholar
- Kole HK, Resnick RJ, Van Doren M, Racker E: Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts. Arch Biochem Biophys. 1991, 286: 586-590. 10.1016/0003-9861(91)90084-VView ArticlePubMedGoogle Scholar
- Racker E, Resnick RJ, Feldman R: Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc Natl Acad Sci U S A. 1985, 82: 3535-3538. 10.1073/pnas.82.11.3535PubMed CentralView ArticlePubMedGoogle Scholar
- Ramanathan A, Wang C, Schreiber SL: Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A. 2005, 102: 5992-5997. 10.1073/pnas.0502267102PubMed CentralView ArticlePubMedGoogle Scholar
- Telang S, Lane AN, Nelson KK, Arumugam S, Chesney J: The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer. 2007, 6: 77- 10.1186/1476-4598-6-77PubMed CentralView ArticlePubMedGoogle Scholar
- Chesney J, Telang S: Regulation of Glycolytic and Mitochondrial Metabolism by Ras. Curr Pharm Biotechnol. 2012, [Epub ahead of print].Google Scholar
- Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS: Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010, 107: 8788-8793. 10.1073/pnas.1003428107PubMed CentralView ArticlePubMedGoogle Scholar
- Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, Miller DM: Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009, 8: 41- 10.1186/1476-4598-8-41PubMed CentralView ArticlePubMedGoogle Scholar
- Minamoto T, Mai M, Ronai Z: K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers–a review. Cancer Detect Prev. 2000, 24: 1-12.PubMedGoogle Scholar
- Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M, Rohlena J, Valis K, Rodriguez-Enriquez S, Butcher B: Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin Cancer Res. 2009, 15: 1593-1600. 10.1158/1078-0432.CCR-08-2439View ArticlePubMedGoogle Scholar
- Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Moreno-Sanchez R: Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med. 2010, 31: 29-59. 10.1016/j.mam.2009.12.006View ArticlePubMedGoogle Scholar
- Gibson BW: The human mitochondrial proteome: oxidative stress, protein modifications and oxidative phosphorylation. Int J Biochem Cell Biol. 2005, 37: 927-934. 10.1016/j.biocel.2004.11.013View ArticlePubMedGoogle Scholar
- Kadenbach B, Huttemann M, Arnold S, Lee I, Bender E: Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. Free Radic Biol Med. 2000, 29: 211-221. 10.1016/S0891-5849(00)00305-1View ArticlePubMedGoogle Scholar
- Kadenbach B, Merle P: On the function of multiple subunits of cytochrome c oxidase from higher eukaryotes. FEBS Lett. 1981, 135: 1-11. 10.1016/0014-5793(81)80932-5View ArticlePubMedGoogle Scholar
- Brookes PS, Levonen AL, Shiva S, Sarti P, Darley-Usmar VM: Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med. 2002, 33: 755-764. 10.1016/S0891-5849(02)00901-2View ArticlePubMedGoogle Scholar
- Capaldi RA: Structure and function of cytochrome c oxidase. Annu Rev Biochem. 1990, 59: 569-596. 10.1146/annurev.bi.59.070190.003033View ArticlePubMedGoogle Scholar
- Kadenbach B, Jarausch J, Hartmann R, Merle P: Separation of mammalian cytochrome c oxidase into 13 polypeptides by a sodium dodecyl sulfate-gel electrophoretic procedure. Anal Biochem. 1983, 129: 517-521. 10.1016/0003-2697(83)90586-9View ArticlePubMedGoogle Scholar
- Anderson WF, Ohlendorf DH, Takeda Y, Matthews BW: Structure of the cro repressor from bacteriophage lambda and its interaction with DNA. Nature. 1981, 290: 754-758. 10.1038/290754a0View ArticlePubMedGoogle Scholar
- Capaldi RA, Marusich MF, Taanman JW: Mammalian cytochrome-c oxidase: characterization of enzyme and immunological detection of subunits in tissue extracts and whole cells. Methods Enzymol. 1995, 260: 117-132.View ArticlePubMedGoogle Scholar
- Campian JL, Gao X, Qian M, Eaton JW: Cytochrome C oxidase activity and oxygen tolerance. J Biol Chem. 2007, 282: 12430-12438. 10.1074/jbc.M604547200View ArticlePubMedGoogle Scholar
- Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF: Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003, 3: 1801-1810. 10.1002/pmic.200300461View ArticlePubMedGoogle Scholar
- Soejima K, Fang W, Rollins BJ: DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene. 2003, 22: 4723-4733. 10.1038/sj.onc.1206510View ArticlePubMedGoogle Scholar
- Srivastava SK, Yuasa Y, Reynolds SH, Aaronson SA: Effects of two major activating lesions on the structure and conformation of human ras oncogene products. Proc Natl Acad Sci U S A. 1985, 82: 38-42. 10.1073/pnas.82.1.38PubMed CentralView ArticlePubMedGoogle Scholar
- Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N: eIF4E–from translation to transformation. Oncogene. 2004, 23: 3172-3179. 10.1038/sj.onc.1207549View ArticlePubMedGoogle Scholar
- Lee S, Kang J, Cho M, Seo E, Choi H, Kim E, Kim J, Kim H, Kang GY, Kim KP: Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol. 2009, 34: 161-172.PubMedGoogle Scholar
- Dejean L, Beauvoit B, Bunoust O, Guerin B, Rigoulet M: Activation of Ras cascade increases the mitochondrial enzyme content of respiratory competent yeast. Biochem Biophys Res Commun. 2002, 293: 1383-1388. 10.1016/S0006-291X(02)00391-1View ArticlePubMedGoogle Scholar
- Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C: Targeting AKT/mTOR and ERK MAPK signalling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008, 118: 3051-3064.PubMed CentralPubMedGoogle Scholar
- Horimoto M, Resnick MB, Konkin TA, Routhier J, Wands JR, Baffy G: Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res. 2004, 10: 6203-6207. 10.1158/1078-0432.CCR-04-0419View ArticlePubMedGoogle Scholar
- Lorenzo M, Valverde AM, Teruel T, Alvarez A, Benito M: p21ras induced differentiation-related gene expression in fetal brown adipocyte primary cells and cell lines. Cell Growth Differ. 1996, 7: 1251-1259.PubMedGoogle Scholar
- Chen Y, Cairns R, Papandreou I, Koong A, Denko NC: Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One. 2009, 4: e7033. 10.1371/journal.pone.0007033PubMed CentralView ArticlePubMedGoogle Scholar
- Taetle R, Rosen F, Abramson I, Venditti J, Howell S: Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep. 1987, 71: 297-304.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.